The $20 million non-dilutive funding and strong cash position reduce near-term financing risk and support execution through the CATT1 topline readout. Traders should monitor enrollment completion in Q3 2026 and any updates on trial progress as key catalysts. However, the widening losses and lack of revenue may pressure sentiment if clinical milestones are delayed.
VTVT drugs
VTVT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 11 $35.10entry
- T+1 · 8mo ago −3.96%α −2.48% · $33.71
- T+5 · 8mo ago +3.42%α +5.61% · $36.30
- T+20 · 7mo ago +6.27%α +5.74% · $37.30
- T+60 · 6mo ago −6.15%α −17.68% · $32.94
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
vTv Therapeutics reported Q4 and full-year 2025 financial results, highlighted by a significant cash increase to $88.9 million from an $80 million financing and a $20 million upfront payment from Newsoara under an amended licensing deal. The company expects to complete enrollment in its Phase 3 CATT1 trial for cadisegliatin in Q3 2026, with a funding runway extending beyond the topline readout. However, net losses widened year-over-year due to higher R&D and G&A expenses.
Key Financial Metrics
Key Facts
- Received $20.0 million upfront from Newsoara in February 2026 under an amended licensing agreement for global rights to PDE4 inhibitor HPP737.
- Cash position was $88.9 million as of December 31, 2025, up from $36.7 million a year prior, driven by $80 million private placement and licensing proceeds.
- Net loss for Q4 2025 was $7.1 million vs. $3.6 million in Q4 2024; full-year 2025 net loss was $27.0 million vs. $18.5 million in 2024.
- R&D expenses increased to $17.9 million in 2025 from $11.5 million in 2024, primarily due to cadisegliatin clinical trials.
- Enrollment in the Phase 3 CATT1 trial is expected to complete in Q3 2026, with topline data to follow.
- No revenue was generated in 2025, compared to $1.0 million in 2024.
Financial Impact
Cash increased by $52.2 million YoY; $20 million non-dilutive licensing inflow in 2026 strengthens near-term liquidity. However, operating losses expanded significantly, with full-year net loss up 46% YoY.
Risk Factors
- Clinical trial delays could push back topline data and increase cash burn.
- Cadisegliatin may fail to demonstrate efficacy or safety in Phase 3, leading to a significant stock decline.
- Future warrant liability fluctuations could create additional non-cash volatility in earnings.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253292 |
Track record
9 reports on VTVT
Filters
- Nov 16, 2026today SC 13D/A Neutral 3/10 Entry $17.69 Now $17.69 +0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $19.69 Now $17.69 −10.16% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $21.03 Now $17.69 −15.88% settles Dec 7
- Oct 8, 20265w ago SC 13G/A Neutral 3/10 Entry $31.18 to $21.03 Now $17.69 −43.26% ▼ −32.55% −26.99% vs SPY
- Jun 10, 202622w ago DEFA14A Neutral 3/10 Entry $31.59 to $33.44 Now $17.69 −44.00% ▲ +5.86% +3.97% vs SPY
- May 8, 202627w ago Press Release Neutral 2/10 Entry $30.46 to $31.77 Now $17.69 −41.92% ▲ +4.30% +4.61% vs SPY
- Mar 10, 202635w ago Press Release Mixed 6/10 Viewing Entry $35.10 to $37.30 Now $17.69 −49.60% ▲ +6.27% +5.74% vs SPY
- Feb 26, 202637w ago 8-K Neutral 4/10 Entry $39.32 to $37.80 Now $17.69 −55.01% ▼ −3.87% +2.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers